Ablynx Receives Milestone Payment as Collaborator Receives IND Approval for a Nanobody in Oncology

News   Apr 06, 2012

 
Ablynx Receives Milestone Payment as Collaborator Receives IND Approval for a Nanobody in Oncology
 
 
 
 

RELATED ARTICLES

Cell Recycling System Offers Therapeutic Entry Point for Rare Disease Treatment

News

Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).

READ MORE

UK Not Ready for Brexit’s Impact on Food, Report Warns

News

Severe problems with the UK food system are likely unless issues are addressed, according to latest expert report

READ MORE

Bone Cancer Drug Targets Tumors, Spares Other Organs

News

A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Applied Sciences

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE